TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with T2DM inadequately controlled with non-insulin, non-injectable anti-hyperglycemic drug(s) and for whom the Investigator/treating physicians has decided that basal insulin is appropriate.~* Signed written informed consent.~Exclusion criteria:~* Glycated hemoglobin A1c (HbA1c) \<7.0% (\<53 mmol/mol) or \>11% (97 mmol/mol) at screening.~* Age \<18 years at the time of screening.~* Body Mass Index (BMI) \>40 kg/m2.~* Diabetes other than T2DM.~* History of T2DM for less than 1 year before screening.~* Less than 6 months anti-hyperglycemic treatment before screening.~* Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit.~* Previous treatment with Glucagon Like Peptide-1 (GLP-1) agonist.~* Patients receiving only non-insulin anti-hyperglycemic drugs not approved for combination with insulin according to local labeling/local treatment guidelines and/or sulfonylurea or glinides.~* Current or previous insulin use except for a maximum of 8 consecutive days and a total of 14 days (eg, acute illness, surgery) during the last year prior to screening.~* Any contraindication to insulin glargine (Lantus) according to the National Product labeling or any excipients.~* Any contraindication to the mandatory background non-insulin anti-hyperglycemic medication according to the respective National Product labeling.~* Latest eye examination by an ophthalmologist \>12 months prior to inclusion.~* More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine U300 (Type: EXPERIMENTAL): Once daily subcutaneous injection for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic proximal PE with or without symptomatic DVT~Exclusion Criteria:~* Legal lower age limitations (country specific)~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE~* Other indication for VKA than DVT and/or PE~* The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
- Enoxaparin/VKA (Type: ACTIVE_COMPARATOR): Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have severe kidney disease~* Subjects who are matched to the kidney disease patients in terms of weight, age, and sex must have normal kidneys~* All women must be post-menopausal (no longer menstruating) or surgically sterile~Exclusion Criteria:~* Patients requiring dialysis~* History of allergy to aspirin or clopidogrel~* Have increased bleeding risk (for instance uncontrolled high blood pressure or a recent major injury)~* Recent history of fainting or light-headedness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AZD6140 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II~* Chinese~* 19-64yr~* Uterus myoma~Exclusion Criteria:~* Allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records.~* Participants younger than 18yr，older than 65yr or pregnancy was eliminated.~* Due to the significant changes in vital signs might affect cognition of pain and that of sensation, over 20% variation of these records from the baselines or below 92% of SpO2 under 20-40% nasal tube oxygen at any time should be excluded from the study.~* Those who were not willing to or could not finish the whole study at any time.~* Any patient who exhibited a combative or incoherent state of PCA analgesia would be excluded from the study.~* Allergy to local anesthetics.~* Failed to perform the epidural catheterization.~* Those who demonstrated significant nerve-associated side effects from the insertion of the epidural needle.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Butorphanol basal infusion adjunct to morphine PCA
- 2 (Type: EXPERIMENTAL): Saline infusion adjunct to morphine PCA
- 3 (Type: EXPERIMENTAL): Premedication of Tramadol
- 4 (Type: EXPERIMENTAL): Preemptive saline for morphine PCA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age~* Documented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML), white blood cells (WBC) ≤ 13,000 /mm\^3, World Health Organization (WHO) that meets International Prognostic Scoring System (IPSS) criteria for low or intermediate-1 risk disease~* Anemia, Hemoglobin (Hgb) ≤ 9.0 g/dL or ≥ 2 units of Red Blood Cells (RBCs) within 84 days~* No response or loss of response to Erythropoiesis-Stimulating Agents (ESAs) or erythropoetin (EPO) \> 500 mU/ml~* Eastern Cooperative Group (ECOG) score ≤2.~* Creatinine \< 1.5 \* Upper Limit of the Normal (ULN)~* Total bilirubin ≤3.0 mg/dL~* Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) \& Alanine Aminotransferase (ALT)/Serum Glutamic Pyruvic (SGPT) ≤3.0 \* Upper Limit of Norma (ULN)~* Free of metastatic malignancy (other than MDS) for ≥2 years~* Highly effective methods of birth control for females and males~Exclusion Criteria:~* Chromosome 5q deletion~* Pregnant or breast feeding women and males who do not agree to use condom during the sexual contact with females of childbearing potential~* Major surgery within 30 days~* Incomplete recovery or incomplete healing of wounds from previous surgery~* Heart failure ≥3 (New York Heart Association (NYHA))~* Thromboembolic or myocardial infarction event within 6 months~* Concurrent anti-cancer cytotoxic chemotherapy~* History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein~* Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B~* Clinically significant anemia unrelated to MDS~* Thrombocytopenia (\<30,000/uL)~* Uncontrolled hypertension~* Treatment with another investigational drug or device within 28 days prior to Day 1~* Prior exposure to sotatercept (ACE-011)~* Any serious medical condition, lab abnormality or psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sotatercept 0.1 mg/kg (Type: EXPERIMENTAL): Sotatercept 0.1 mg/kg
- Sotatercept 0.3 mg/kg (Type: EXPERIMENTAL): Sotatercept 0.3 mg/kg
- Sotatercept 0.5 mg/kg (Type: EXPERIMENTAL): Sotatercept 0.5 mg/kg
- Sotatercept 1.0 mg/kg (Type: EXPERIMENTAL): Sotatercept 1.0 mg/kg
- Sotatercept 1.5 mg/kg (Type: EXPERIMENTAL): Sotatercept 1.5 mg/kg
- Sotatercept 2.0 mg/kg (Type: EXPERIMENTAL): Sotatercept 2.0 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients 18 years of age or older currently being treated with an ACE-I or ARB and with one of the following conditions:~1. Non-nephrotic range proteinuria (between 1 and 3 grams/day by 24-hr collection), hypertension (blood pressure \>130/80 or current use of antihypertensive drug therapy), and an eGFR of less than or equal to 40 ml/minute but greater than 20 ml/minute.~   OR~2. Nephrotic range proteinuria (\>=3 grams/day proteinuria) by 24-hr urine collection, and an eGFR greater than 20 ml/minute~Exclusion Criteria:~1. Acute renal failure: defined by \>25% decrease in eGFR over one month~2. Pregnancy or currently breast-feeding~3. Current use of cytotoxic drug therapy (cyclophosphamide, cyclosporine, mycophenolate mofetil, prednisone, chlorambucil) or a current indication for, and plan to implement, such therapy.~4. Current use of PTF~5. Contraindication to use of PTF drug: history of PTF or theophylline allergy, history of severe retinal hemorrhage or recent cerebral hemorrhage~6. Current use of theophylline~7. Contraindication to ACE-I or ARB.~8. Fewer than 2 measured serum creatinine values separated by 6 months prior to potential enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years of age upon entry into screening~* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)~* ≥ 4 monthly headache days on average across the 3 months prior to screening~* Provision of informed consent prior to initiation of any study-specific activities/procedures.~Exclusion Criteria:~* \> 1 mild traumatic injury to the head~* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)~* History of moderate or severe injury to the head~* History of whiplash injury~* History of craniotomy~* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion~* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior~* Female subjects of childbearing potential with a positive pregnancy test during any study visit~* Cardiovascular disease of any kind, including cerebrovascular diseases~* Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day~* Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)~* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion~* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start~* Baseline headache intensity of \>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)~* Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Levcromakalim (Type: EXPERIMENTAL): A time- and volume-controlled infusion pump is used to administer levcromakalim by intravenous infusion over 20 minutes.
- Placebo (isotonic saline) (Type: PLACEBO_COMPARATOR): A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy heterosexual males between the ages of 16 years and 23 years and 364 days. Healthy men having sex with men (MSM) between the ages of 16 years and 26 years and 364 days.~* No clinical evidence of genital lesions suggesting sexually-transmitted disease, and no history of anogenital warts~* Additional criteria will be discussed with you by the physician~Exclusion Criteria:~* Concurrently enrolled in a clinical study involving collection of genital specimens~* History of known prior vaccination with an HPV vaccine~* Received an inactivated vaccine within 14 days or a live virus vaccine within 21 days prior to enrollment~* History of a severe allergic reaction that required medical intervention~* Received any immune globulin or blood-derived products within 6 months prior to the first study injection~* History of splenectomy, immune disorders, or receiving immunosuppressives~* Immunocompromised or diagnosed with HIV infection~* Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections~* History of recent or ongoing alcohol or drug abuse

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- qHPV Vaccine (Type: EXPERIMENTAL): The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
- Placebo (Type: PLACEBO_COMPARATOR): The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modified Pectoral Nerves Block Versus Serratus Plane Block in Major Breast Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists( ASA) I or II and scheduled for major breast cancer surgery( modified radical mastectomy or conservative mastectomy with axillary evacuation).~Exclusion Criteria:~* Local infection at the site of the block, coagulations abnormalities, allergy to local anesthetics or morphine, body mass index\> 35, patient refusal, severe respiratory or cardiac disorders, pre-existing neurological deficits, hepatic or renal insufficiency, chronic pain syndrome, chronic analgesic use and psychiatric disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- modified pectoral nerves block (Type: ACTIVE_COMPARATOR): Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
- serratus plane block (Type: ACTIVE_COMPARATOR): Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents aged 10 through 25 years of age inclusive at the time of enrollment.~Exclusion Criteria:~* History of any meningococcal vaccine administration;~* Current or previous, confirmed or suspected disease caused by N. meningitidis;~* Pregnant or nursing (breastfeeding) mothers;~* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study;~* Any serious, chronic, or progressive disease;~* Known or suspected impairment/alteration of the immune system;~* Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;~* History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- ABCWY+OMV (Type: EXPERIMENTAL): Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart.
- ABCWY+qOMV (Type: EXPERIMENTAL): Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart.
- rMenB+OMV (Type: ACTIVE_COMPARATOR): Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart.
- MenACWY (Type: ACTIVE_COMPARATOR): Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete